Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.

Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB.

Chest. 2019 Mar;155(3):565-586. doi: 10.1016/j.chest.2018.11.030. Epub 2019 Jan 17.

PMID:
30660783
2.

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.

Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801887. doi: 10.1183/13993003.01887-2018. Print 2019 Jan.

3.

Chronic Thromboembolic Pulmonary Hypertension.

Mullin CJ, Klinger JR.

Heart Fail Clin. 2018 Jul;14(3):339-351. doi: 10.1016/j.hfc.2018.02.009. Review.

PMID:
29966632
4.

Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.

Baird GL, Archer-Chicko C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P, Palevsky HI, Palmisicano AJ, Pinder D, Preston IR, Roberts KE, Smith KA, Walsh T, Whittenhall M, Ventetuolo CE.

Eur Respir J. 2018 Jun 28;51(6). pii: 1800467. doi: 10.1183/13993003.00467-2018. Print 2018 Jun.

PMID:
29954925
5.

Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database.

Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA.

PLoS One. 2017 Nov 9;12(11):e0187734. doi: 10.1371/journal.pone.0187734. eCollection 2017.

6.

The Nitric Oxide Pathway in Pulmonary Vascular Disease.

Klinger JR, Kadowitz PJ.

Am J Cardiol. 2017 Oct 15;120(8S):S71-S79. doi: 10.1016/j.amjcard.2017.06.012. Review.

7.

Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension.

Liang OD, So EY, Egan PC, Goldberg LR, Aliotta JM, Wu KQ, Dubielecka PM, Ventetuolo CE, Reginato AM, Quesenberry PJ, Klinger JR.

Cardiovasc Res. 2017 Nov 1;113(13):1560-1573. doi: 10.1093/cvr/cvx161.

8.

Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo.

Stewart LK, Nordenholz KE, Courtney M, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Kline JA.

Blood Coagul Fibrinolysis. 2017 Dec;28(8):675-680. doi: 10.1097/MBC.0000000000000669.

PMID:
28957940
9.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

10.

Echocardiographic Pulmonary Hypertension Predicts Post-transplantation Renal Allograft Failure.

Foderaro AE, Baird GL, Bazargan-Lari A, Morrissey PE, Gohh RY, Poppas A, Klinger JR, Ventetuolo CE.

Transplant Proc. 2017 Jul - Aug;49(6):1256-1261. doi: 10.1016/j.transproceed.2017.01.085.

11.

The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension.

Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE.

Pulm Circ. 2017 Apr-Jun;7(2):384-390. doi: 10.1177/2045893217695568. Epub 2017 Mar 16.

12.

Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model.

Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Cheng Y, Goldberg L, Ventetuolo CE, Liang O, Klinger JR, Quesenberry PJ.

Stem Cells Transl Med. 2017 Jul;6(7):1595-1606. doi: 10.1002/sctm.16-0386. Epub 2017 May 5.

13.

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.

Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.

14.

Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?

Klinger JR.

Eur Respir J. 2016 Nov;48(5):1265-1267. doi: 10.1183/13993003.01542-2016. No abstract available.

15.

Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.

Kawut SM, Archer-Chicko CL, DeMichele A, Fritz JS, Klinger JR, Ky B, Palevsky HI, Palmisciano AJ, Patel M, Pinder D, Propert KJ, Smith KA, Stanczyk F, Tracy R, Vaidya A, Whittenhall ME, Ventetuolo CE.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):360-368. doi: 10.1164/rccm.201605-1024OC.

16.

Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments.

Klinger JR.

Cardiol Clin. 2016 Aug;34(3):413-33. doi: 10.1016/j.ccl.2016.04.003. Review.

PMID:
27443138
17.

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.

Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR.

Chest. 2017 Feb;151(2):468-480. doi: 10.1016/j.chest.2016.05.024. Epub 2016 Jun 2. Review.

18.

Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation.

Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR.

Pulm Circ. 2016 Jun;6(2):191-5. doi: 10.1086/686489.

19.

Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.

Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Goldberg LR, Baird GL, Ventetuolo CE, Quesenberry PJ, Klinger JR.

Cardiovasc Res. 2016 Jun 1;110(3):319-30. doi: 10.1093/cvr/cvw054. Epub 2016 Mar 14.

20.

Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM.

Am J Respir Crit Care Med. 2016 May 15;193(10):1168-75. doi: 10.1164/rccm.201509-1785OC.

21.

Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.

Fowler RA, Mittmann N, Geerts WH, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

Trials. 2014 Dec 20;15:502. doi: 10.1186/1745-6215-15-502.

22.

Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism.

Stewart LK, Peitz GW, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Kline JA.

J Thromb Thrombolysis. 2015 Aug;40(2):161-6. doi: 10.1007/s11239-014-1155-5.

23.

Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection.

Sangal RB, Taylor LE, Gillani F, Poppas A, Klinger JR, Ventetuolo CE.

Ann Am Thorac Soc. 2014 Dec;11(10):1553-9. doi: 10.1513/AnnalsATS.201405-225OC.

24.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
25.

Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.

Berman-Rosenzweig E, Arneson C, Klinger JR.

Pulm Circ. 2014 Mar;4(1):45-52. doi: 10.1086/674901.

26.

Are hemodynamics surrogate end points in pulmonary arterial hypertension?

Ventetuolo CE, Gabler NB, Fritz JS, Smith KA, Palevsky HI, Klinger JR, Halpern SD, Kawut SM.

Circulation. 2014 Aug 26;130(9):768-75. doi: 10.1161/CIRCULATIONAHA.114.009690. Epub 2014 Jun 20.

27.

Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB.

Chest. 2014 Aug;146(2):449-475. doi: 10.1378/chest.14-0793. Review.

28.

Management of acute right ventricular failure in the intensive care unit.

Ventetuolo CE, Klinger JR.

Ann Am Thorac Soc. 2014 Jun;11(5):811-22. doi: 10.1513/AnnalsATS.201312-446FR. Review.

29.

Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial.

Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, Albert M, Dodek P, Finfer S, Vallance S, Heels-Ansdell D, McIntyre L, Mehta S, Lamontagne F, Muscedere J, Jacka M, Lesur O, Kutsiogiannis J, Friedrich J, Klinger JR, Qushmaq I, Burry L, Khwaja K, Sheppard JA, Warkentin TE; PROTECT collaborators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group.

J Crit Care. 2014 Jun;29(3):470.e7-15. doi: 10.1016/j.jcrc.2014.02.004. Epub 2014 Feb 14.

PMID:
24726205
30.

Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial.

Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J.

J Thromb Haemost. 2014 Apr;12(4):459-68. doi: 10.1111/jth.12521.

31.

Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.

Channick R, Preston I, Klinger JR.

Clin Chest Med. 2013 Dec;34(4):811-24. doi: 10.1016/j.ccm.2013.09.005. Review.

PMID:
24267306
32.

Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes.

Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, Nordenholz KE, Diercks DB, Rondina MT, Klinger JR.

Emerg Med Australas. 2013 Dec;25(6):515-26. doi: 10.1111/1742-6723.12159. Epub 2013 Nov 13.

PMID:
24224521
33.

Sex and haemodynamics in pulmonary arterial hypertension.

Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM.

Eur Respir J. 2014 Feb;43(2):523-30. doi: 10.1183/09031936.00027613. Epub 2013 Aug 15.

34.

Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice.

Aliotta JM, Pereira M, Amaral A, Sorokina A, Igbinoba Z, Hasslinger A, El-Bizri R, Rounds SI, Quesenberry PJ, Klinger JR.

Cardiovasc Res. 2013 Dec 1;100(3):354-62. doi: 10.1093/cvr/cvt184. Epub 2013 Jul 18.

35.

Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.

Klinger JR, Abman SH, Gladwin MT.

Am J Respir Crit Care Med. 2013 Sep 15;188(6):639-46. doi: 10.1164/rccm.201304-0686PP. Review.

PMID:
23822809
36.

Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A.

Klinger JR, Tsai SW, Green S, Grinnell KL, Machan JT, Harrington EO.

J Appl Physiol (1985). 2013 Feb;114(3):307-15. doi: 10.1152/japplphysiol.01249.2011. Epub 2012 Nov 29.

37.

WHO Group 1 pulmonary arterial hypertension: current and investigative therapies.

Ventetuolo CE, Klinger JR.

Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):89-103. doi: 10.1016/j.pcad.2012.07.002. Review.

PMID:
23009906
38.

Genetic disruption of protein kinase Cδ reduces endotoxin-induced lung injury.

Chichger H, Grinnell KL, Casserly B, Chung CS, Braza J, Lomas-Neira J, Ayala A, Rounds S, Klinger JR, Harrington EO.

Am J Physiol Lung Cell Mol Physiol. 2012 Nov 15;303(10):L880-8. doi: 10.1152/ajplung.00169.2012. Epub 2012 Sep 14.

39.

Partial anomalous pulmonary venous return presenting with adult-onset pulmonary hypertension.

Sears EH, Aliotta JM, Klinger JR.

Pulm Circ. 2012 Apr-Jun;2(2):250-5. doi: 10.4103/2045-8932.97637.

40.

The case for increased funding for research in pulmonary and critical care.

Peters-Golden M, Klinger JR, Carson SS; ATS Research Advocacy Committee.

Am J Respir Crit Care Med. 2012 Aug 1;186(3):213-5. Epub 2012 May 10. Review.

PMID:
22582163
41.

Initial risk assessment for pulmonary hypertension in patients with COPD.

Gartman EJ, Blundin M, Klinger JR, Yammine J, Roberts MB, Dennis McCool F.

Lung. 2012 Feb;190(1):83-9. doi: 10.1007/s00408-011-9346-8. Epub 2011 Nov 18.

PMID:
22094960
42.

Diagnosis and management of pulmonary arterial hypertension.

Houtchens J, Martin D, Klinger JR.

Pulm Med. 2011;2011:845864. doi: 10.1155/2011/845864. Epub 2011 Sep 20.

43.

Combination therapy for the treatment of pulmonary arterial hypertension.

Levinson AT, Klinger JR.

Ther Adv Respir Dis. 2011 Dec;5(6):419-30. doi: 10.1177/1753465811411602. Epub 2011 Aug 17. Review.

PMID:
21849335
44.

C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.

Casserly B, Mazer JM, Vang A, Harrington EO, Klinger JR, Rounds S, Choudhary G.

Life Sci. 2011 Sep 26;89(13-14):460-6. doi: 10.1016/j.lfs.2011.07.009. Epub 2011 Jul 27.

45.

Pulmonary hypertension in a stable community-based COPD population.

Fayngersh V, Drakopanagiotakis F, Dennis McCool F, Klinger JR.

Lung. 2011 Oct;189(5):377-82. doi: 10.1007/s00408-011-9315-2. Epub 2011 Aug 4.

PMID:
21814783
46.

Tadalafil for the treatment of pulmonary arterial hypertension.

Klinger JR.

Expert Rev Respir Med. 2011 Jun;5(3):315-28. doi: 10.1586/ers.11.38. Review.

PMID:
21702653
47.

Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease.

Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR.

Lung. 2011 Jun;189(3):207-12. doi: 10.1007/s00408-011-9293-4. Epub 2011 May 10.

PMID:
21556789
48.

Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.

Choudhary G, Troncales F, Martin D, Harrington EO, Klinger JR.

J Heart Lung Transplant. 2011 Jul;30(7):827-33. doi: 10.1016/j.healun.2011.03.010. Epub 2011 May 8.

49.

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.

Am J Cardiol. 2011 Jul 15;108(2):302-7. doi: 10.1016/j.amjcard.2011.03.037. Epub 2011 May 3.

PMID:
21545989
50.

Pulmonary puzzle. An unusual cause of chest pain. Diagnosis: Cor triatriatum sinistrum with secondary unilateral pulmonary venous hypertension and right lung hypoplasia.

Casserly B, Atalay MK, Poppas A, Klinger JR, Abu-Hijleh M.

Thorax. 2011 Apr;66(4):285-6, 313-4. doi: 10.1136/thx.2010.141689. No abstract available.

PMID:
21071763

Supplemental Content

Loading ...
Support Center